All News Karolinska Development AB

Equities

KDEV

SE0002190926

Market Closed - Nasdaq Stockholm Other stock markets 11:29:44 2024-05-21 am EDT			5-day change	1st Jan Change
1.562 ^SEK	-2.38%		-6.47%	-8.01%

Apr. 26	Karolinska Development AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 16	Karolinska Development AB Announces That Björn Cochlovius Has Declined Re-Election	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Karolinska Development : Annual General Meeting 2024	May. 16	PU
Karolinska Development’s Annual General Meeting 2024	May. 16	GL
Karolinska Development’s portfolio company Umecrine Cognition initiates second part of clinical phase 1a/2 study in PBC	May. 08	GL
Interim Report - January-March 2024	Apr. 26	GL
Karolinska Development AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26	CI
Notice of Annual General Meeting in Karolinska Development AB (publ)	Apr. 16	GL
Karolinska Development AB Announces That Björn Cochlovius Has Declined Re-Election	Apr. 16	CI
Karolinska Development : portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC	Mar. 22	PU
Karolinska Development’s portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC	Mar. 22	GL
Karolinska Development Annual Report 2023 published	Mar. 22	GL
Karolinska Development Annual Report 2023 published	Mar. 22	AQ
Karolinska Development : portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million	Mar. 14	PU
Karolinska Development’s portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million	Mar. 14	GL
Karolinska Development : portfolio company Biosergen publishes prospectus due to rights issue of units	Mar. 14	PU
Karolinska Development’s portfolio company Biosergen publishes prospectus due to rights issue of units	Mar. 14	GL
Karolinska Development : portfolio company Umecrine Cognition presents preclinical Parkinson's data on golexanolone at AD/PD	Mar. 06	PU
Karolinska Development’s portfolio company Umecrine Cognition presents preclinical Parkinson’s data on golexanolone at AD/PD	Mar. 06	GL
Year-end Report - January-December 2023	Feb. 16	GL
Karolinska Development AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 16	CI
Karolinska Development Portfolio Company AnaCardio Completes SEK150 Million Funding Round	Jan. 17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Karolinska Development AB

Equities

KDEV

SE0002190926

All News

Filters